Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers

Open access

Published version of a preprint

Abstract

The most common oncogenic driver mutations for non–small cell lung cancer (NSCLC) activate EGFR or KRAS. Clinical trials exploring treatments for EGFR- or KRAS-mutated (EGFRmut or KRASmut) cancers have focused on small-molecule inhibitors targeting the driver mutations. Typically, these inhibitors perform more effectively based on combination with either chemotherapies, or other targeted therapies. For EGFRmut NSCLC, a combination of inhibitors of EGFR and Aurora-A kinase (AURKA), an oncogene commonly overexpressed in solid tumors, has shown promising activity in clinical trials. Interestingly, a number of recent studies have indicated that EGFR activity supports overall viability of tumors lacking EGFR mutations, and AURKA expression is abundant in KRASmut cell lines. In this study, we have evaluated dual inhibition of EGFR and AURKA in KRASmut NSCLC models. These data demonstrate synergy between the EGFR inhibitor erlotinib and the AURKA inhibitor alisertib in reducing cell viability and clonogenic capacity in vitro, associated with reduced activity of EGFR pathway effectors, accumulation of enhanced aneuploid cell populations, and elevated cell death. Importantly, the erlotinib-alisertib combination also synergistically reduces xenograft growth in vivo. Analysis of signaling pathways demonstrated that the combination of erlotinib and alisertib was more effective than single-agent treatments at reducing activity of EGFR and pathway effectors following either brief or extended administration of the drugs. In sum, this study indicates value of inhibiting EGFR in KRASmut NSCLC, and suggests the specific value of dual inhibition of AURKA and EGFR in these tumors. Significance: The introduction of specific KRAS G12C inhibitors to the clinical practice in lung cancer has opened up opportunities that did not exist before. However, G12C alterations are only a subtype of all KRAS mutations observed. Given the high expression of AURKA in KRASmut NSCLC, our study could point to a potential therapeutic option for this subgroup of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2767-9764.crc-23-0482

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Expression of AURKA and EGFR in NSCLC. A, EGFR mRNA expression in KRASmut versus EGFRmut NSCLC, from a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. B, EGFR protein expression in KRASmut versus EGFRmut in LUAD PanCancer study. Expression data are presented as RPPA z-scored values (356 samples). C, AURKA mRNA expression in KRASmut versus EGFRmut NSCLC, in a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. D,AURKA copy-number changes dependent on mutation status of KRAS, EGFR, and TP53, in a combined set of 411 samples (LUAD PanCancer, OncoSG, and CPTAC studies). E, AURKA mRNA expression in KRASmut versus EGFRmut NSCLC based on TP53 mutation status, in a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. F, EGFR mRNA expression in KRASmut versus EGFRmut NSCLC based on TP53 mutation status in combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. See Materials and Methods for details of data retrieval and analysis.
FIGURE 1 Expression of AURKA and EGFR in NSCLC. A, EGFR mRNA expression in KRASmut versus EGFRmut NSCLC, from a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. B, EGFR protein expression in KRASmut versus EGFRmut in LUAD PanCancer study. Expression data are presented as RPPA z-scored values (356 samples). C, AURKA mRNA expression in KRASmut versus EGFRmut NSCLC, in a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. D,AURKA copy-number changes dependent on mutation status of KRAS, EGFR, and TP53, in a combined set of 411 samples (LUAD PanCancer, OncoSG, and CPTAC studies). E, AURKA mRNA expression in KRASmut versus EGFRmut NSCLC based on TP53 mutation status, in a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. F, EGFR mRNA expression in KRASmut versus EGFRmut NSCLC based on TP53 mutation status in combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. See Materials and Methods for details of data retrieval and analysis.CC BY · PubMed Central
FIGURE 2 Sensitivity of NSCLC cell lines to erlotinib and alisertib. A, Western blot images and quantification of the protein levels of EGFR and AURKA in NSCLC cell lines and the human fibroblast cell line FC1010. Data for NSCLC cell lines are normalized to the levels in FC1010 cells. B, Determination of AURKA gene copy number in NSCLC cell lines, using the colorectal cancer cell lines HCT116 and SW420 as standards. Normalization to RNAseP, blue, or ALB, orange. The slopes of the standard curves were −3.64 (AURKA), −3,46 (RNAseP), −3.49 (ALB). Determination of sensitivity of the NSCLC cell lines and FC1010 control to erlotinib (C) and alisertib (D), with quantified IC50 values (E), based on CelltiterBlue analysis of viability after growth with indicated drugs for 72 hours. N/A, IC50s were not calculated because of low sensitivity to the drug. F, Combination indexes for erlotinib and alisertib over a range of molar ratios. Results shown reflect averages from four to five independent experiments, each done in quadruplicate, ± SEM and were calculated using CompuSyn software.
FIGURE 2 Sensitivity of NSCLC cell lines to erlotinib and alisertib. A, Western blot images and quantification of the protein levels of EGFR and AURKA in NSCLC cell lines and the human fibroblast cell line FC1010. Data for NSCLC cell lines are normalized to the levels in FC1010 cells. B, Determination of AURKA gene copy number in NSCLC cell lines, using the colorectal cancer cell lines HCT116 and SW420 as standards. Normalization to RNAseP, blue, or ALB, orange. The slopes of the standard curves were −3.64 (AURKA), −3,46 (RNAseP), −3.49 (ALB). Determination of sensitivity of the NSCLC cell lines and FC1010 control to erlotinib (C) and alisertib (D), with quantified IC50 values (E), based on CelltiterBlue analysis of viability after growth with indicated drugs for 72 hours. N/A, IC50s were not calculated because of low sensitivity to the drug. F, Combination indexes for erlotinib and alisertib over a range of molar ratios. Results shown reflect averages from four to five independent experiments, each done in quadruplicate, ± SEM and were calculated using CompuSyn software.CC BY · PubMed Central
FIGURE 3 Signaling, cell cycle, and clonogenic analysis of combined erlotinib and alisertib in KRASmut NSCLC cells. A, Quantification of Western analysis of drug-treated cells using indicated antibodies, based on five to eight replicates. Cells were treated for 24 hours with concentrations reflecting the IC80 value of erlotinib and/or alisertib (9 µmol/L erlotinib: 13 µmol/L alisertib, in A549 cells, or 2.8 µmol/L erlotinib: 4.2 µmol/L alisertib in H358 cells). Primary Western blot data are shown in Supplementary Fig. S1. B, FACS analysis of cell cycle in H358 and A549 cells treated for 24 or 72 hours with drug concentrations 0.2 µmol/L erlotinib: 300 nmol/L alisertib, in A549 cells, or 1.2 µmol/L erlotinib: 1.8 µmol/L alisertib in H358 cells; three to four biological replicates, data shown represent averaged values. Representative data from clonogenic assays (C) and quantitation of images from three biological replicates (D), for the indicated cell lines treated with negative control, 75 nmol/L erlotinib, 25 nmol/L alisertib, or the combination for 10 days. Statistical comparisons are to control (red), combination to erlotinib (orange) or alisertib (green), alisertib to erlotinib (purple). *, P < 0.05; **, P < 0.01; ***, P < 0.001. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.
FIGURE 3 Signaling, cell cycle, and clonogenic analysis of combined erlotinib and alisertib in KRASmut NSCLC cells. A, Quantification of Western analysis of drug-treated cells using indicated antibodies, based on five to eight replicates. Cells were treated for 24 hours with concentrations reflecting the IC80 value of erlotinib and/or alisertib (9 µmol/L erlotinib: 13 µmol/L alisertib, in A549 cells, or 2.8 µmol/L erlotinib: 4.2 µmol/L alisertib in H358 cells). Primary Western blot data are shown in Supplementary Fig. S1. B, FACS analysis of cell cycle in H358 and A549 cells treated for 24 or 72 hours with drug concentrations 0.2 µmol/L erlotinib: 300 nmol/L alisertib, in A549 cells, or 1.2 µmol/L erlotinib: 1.8 µmol/L alisertib in H358 cells; three to four biological replicates, data shown represent averaged values. Representative data from clonogenic assays (C) and quantitation of images from three biological replicates (D), for the indicated cell lines treated with negative control, 75 nmol/L erlotinib, 25 nmol/L alisertib, or the combination for 10 days. Statistical comparisons are to control (red), combination to erlotinib (orange) or alisertib (green), alisertib to erlotinib (purple). *, P < 0.05; **, P < 0.01; ***, P < 0.001. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.CC BY · PubMed Central
FIGURE 4 Combination of erlotinib and alisertib enhances suppression of KRASmut NSCLC xenograft growth. A549 (A) and H358 (B) tumor xenografts, were treated with 10 mg/kg erlotinib, daily, and 10 mg/kg alisertib, twice daily, for 21 days. n = 5–8 for all groups. §, P < 0.001; #, additive effect; ##, synergistic effect (P = 0.011). Body weight of mice treated with erlotinib, alisertib or both for 21 days, from cohort shown in A (C) and B (D). Representative images and H-scores for Ki-67 (E, F) and cleaved caspase-3 (G, H) staining in A549 and H358 tumor xenografts treated with 10 mg/kg erlotinib, daily, 10 mg/kg alisertib, twice a day, or both for 21 days (mean ± SEM, n = 4–8). Scale bar, 100 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001, significantly different from comparison groups. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib; purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.
FIGURE 4 Combination of erlotinib and alisertib enhances suppression of KRASmut NSCLC xenograft growth. A549 (A) and H358 (B) tumor xenografts, were treated with 10 mg/kg erlotinib, daily, and 10 mg/kg alisertib, twice daily, for 21 days. n = 5–8 for all groups. §, P < 0.001; #, additive effect; ##, synergistic effect (P = 0.011). Body weight of mice treated with erlotinib, alisertib or both for 21 days, from cohort shown in A (C) and B (D). Representative images and H-scores for Ki-67 (E, F) and cleaved caspase-3 (G, H) staining in A549 and H358 tumor xenografts treated with 10 mg/kg erlotinib, daily, 10 mg/kg alisertib, twice a day, or both for 21 days (mean ± SEM, n = 4–8). Scale bar, 100 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001, significantly different from comparison groups. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib; purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.CC BY · PubMed Central
FIGURE 5 Signaling patterns in KRASmut NSCLC xenografts after extended treatment with erlotinib and alisertib. Quantification of Western blot images for A549 tumors (A), with summary of analytes for which the result with the erlotinib+alisertib combination but not with any single drug differed significantly from the vehicle-treated control (B); data are presented as mean ± SEM, n = 4–8 mice. In A549, phospho-AURKA activity was determined by an MSD kit and normalized to the protein content; total AURKA was assessed by Western blotting. In H358, both AURKA forms were measured by Western blotting. Results as for A and B, but showing quantified data (C) and summary analysis (D) for H358 tumors. Primary Western blot data for both tumor models are shown in Supplementary Figs. S2 and S3. *, Significantly different from corresponding groups with P < 0.05; **, P < 0.01; or ***, P < 0.001. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib, purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.
FIGURE 5 Signaling patterns in KRASmut NSCLC xenografts after extended treatment with erlotinib and alisertib. Quantification of Western blot images for A549 tumors (A), with summary of analytes for which the result with the erlotinib+alisertib combination but not with any single drug differed significantly from the vehicle-treated control (B); data are presented as mean ± SEM, n = 4–8 mice. In A549, phospho-AURKA activity was determined by an MSD kit and normalized to the protein content; total AURKA was assessed by Western blotting. In H358, both AURKA forms were measured by Western blotting. Results as for A and B, but showing quantified data (C) and summary analysis (D) for H358 tumors. Primary Western blot data for both tumor models are shown in Supplementary Figs. S2 and S3. *, Significantly different from corresponding groups with P < 0.05; **, P < 0.01; or ***, P < 0.001. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib, purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.CC BY · PubMed Central
FIGURE 6 Signaling patterns in KRASmut NSCLC xenografts 6 or 24 hours after treatment with erlotinib or/and alisertib. Quantification of Western blot images for A549 (A) xenograft tumors. Data are presented as mean ± SEM, n = 3–6 mice. B, Summary for A549 xenografts shows significant changes in protein levels and activation after erlotinib+alisertib treatment, in reference to vehicle treated control group. C, Quantification of Western blots for H358 xenograft tumors. Primary Western blot data are shown in Supplementary Figs. S4 and S5. *, Significantly different from corresponding groups with P < 0.05; **, P < 0.01; or ***, P < 0.001. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib, purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.
FIGURE 6 Signaling patterns in KRASmut NSCLC xenografts 6 or 24 hours after treatment with erlotinib or/and alisertib. Quantification of Western blot images for A549 (A) xenograft tumors. Data are presented as mean ± SEM, n = 3–6 mice. B, Summary for A549 xenografts shows significant changes in protein levels and activation after erlotinib+alisertib treatment, in reference to vehicle treated control group. C, Quantification of Western blots for H358 xenograft tumors. Primary Western blot data are shown in Supplementary Figs. S4 and S5. *, Significantly different from corresponding groups with P < 0.05; **, P < 0.01; or ***, P < 0.001. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib, purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 15

Metadata

Authors
Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H.
Affiliations
Fox Chase Cancer Center (US)
Corresponding author
Borghaei, Hossein
Venue
Cancer Research Communications
Published
2024-05-08
Volume
4
Issue
5
Pages
1227-1239
ISSN
2767-9764 (ISSN-L)
OpenAlex
W4394941922
Cited by
14
References
67
Citations by year
2026: 5 · 2025: 8 · 2024: 1
FWCI
4.04
Type
journal article
Language
en
Open access
Locations
  • Cancer Research Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • TUScholarShare (Temple University) (submittedVersion, cc-by)
Funders
  • HHS | NIH | National Cancer Institute (P30 CA006927)
  • William Wikoff Smith Charitable Trust
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
non-small cell lung cancer, KRAS mutation, EGFR inhibition, erlotinib, alisertib, combination therapy, drug synergy, aneuploidy, clonogenicity, xenograft tumor growth, KRAS G12C inhibitors
MeSH terms
Erlotinib Hydrochloride, Animals, Antineoplastic Combined Chemotherapy Protocols, Azepines, Carcinoma, Non-Small-Cell Lung, Drug Synergism, Humans, Lung Neoplasms, Mutation, Pyrimidines, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Aurora Kinase A, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers. https://app.cochat.ai/papers/10.1158/2767-9764.crc-23-0482
The paper
Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H. (2024). Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-23-0482

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.